Int'l Neuroblastoma Webinar Series Session #21: ALK in Neuroblastoma with Dr. Claudia Pasqualini

A look at ALK in neuroblastoma and the targeted therapies now aimed at it, featuring Dr. Claudia Pasqualini of Gustave Roussy in Paris. In Session #21 of our global Neuroblastoma Webinar Series, Dr. Pasqualini explains what an ALK change is, how it drives some neuroblastomas, and why it has become one of the most important targets in the field. She offers a plain-language look at how common ALK alterations are and which children they affect, where ALK inhibitors sit in the current trial landscape, and how testing guides treatment decisions. The session closes with a live audience Q&A. Designed for both families and professionals, this conversation makes a complex area of precision medicine understandable and explores what it means for children facing the disease today. In this session: What ALK is, and how ALK changes drive some neuroblastomas How common ALK alterations are, and which children they affect A plain-language look at ALK inhibitors and the trials testing them How ALK testing guides treatment decisions Live Q&A with Dr. Pasqualini About the speaker: Dr. Claudia Pasqualini is a pediatric oncologist at Gustave Roussy in Paris, a member of the SIOPEN Executive Committee, where she leads the international HRNBL2 study for high-risk neuroblastoma. This session was supported by United Therapeutics. Explore more: 🎥 Watch past and upcoming sessions: https://neuroblastomaday.org/global-webinar 💙 Learn about Shir for Life: neuroblastomaday.org Register for the next session: https://neuroblastomaday.org/webinar